Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Heilbronn – page 53

987 clinical trials in Heilbronn, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Heilbronn at a glance
987
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

987 trials in Heilbronn

Open in trial search

Head and neck cancer metastatic

Not recruiting

Study of eftilagimod alpha with pembrolizumab combination therapy for patients with metastatic head and neck cancer who have not received previous treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Eftilagimod Alfa
  • Sponsor:Immutep

Neurodermatitis

Not recruiting

Study on the Effects of Barzolvolimab for Patients with Prurigo Nodularis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Celldex Therapeutics Inc.

Non-small cell lung cancer stage III+2

Not recruiting

Study on Thoracic Radiotherapy and Durvalumab for Elderly or Frail Stage III Non-Small Cell Lung Cancer Patients Unable to Undergo Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Cholangiocarcinoma

Not recruiting

Study of Pemigatinib for Patients with Advanced Intrahepatic Cholangiocarcinoma with FGFR2 Changes After Local Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pemigatinib
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Cholangitis sclerosing

Not recruiting

Study on the Safety and Effectiveness of Elafibranor for Adults with Primary Sclerosing Cholangitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Amyloidosis

Not recruiting

Study of Belantamab Mafodotin for Patients with Relapsed or Refractory AL Amyloidosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Non-small cell lung cancer+2

Not recruiting

Study of AMG 193 alone and combined with docetaxel for treatment of advanced MTAP-null solid tumors in adult patients

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AMG 193
  • Sponsor:Amgen Inc.

B-cell lymphoma refractory

Not recruiting

Study on Tafasitamab with Gemcitabine, Oxaliplatin, and Rituximab for Patients with Aggressive B-cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin
  • Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Idiopathic pulmonary fibrosis+1

Not recruiting

Study on BI 1839100 for Reducing Cough in Patients with Idiopathic or Progressive Pulmonary Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 1839100
  • Sponsor:Boehringer Ingelheim Espana S.A.

Non-small cell lung cancer+1

Not recruiting

Study on Durvalumab and Chemotherapy for Patients with Resectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Universitaetsklinikum Essen AöR

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Heilbronn

What the registry says about research in the country

01 Blood Cancers

Innovative trials focusing on Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia, testing novel drug combinations to improve patient outcomes. Research includes evaluating treatments for both adult and pediatric patients with various forms of leukemia.

  • Novel drug combinations for AML treatment
  • Targeted therapies for specific genetic mutations
  • Pediatric leukemia protocols

Studies aim to enhance survival rates and develop more effective treatment strategies for blood cancer patients.

02 Breast Cancer Research

Comprehensive studies addressing different types of breast cancer, particularly focusing on triple-negative breast cancer and HER2-positive disease. Research includes both early-stage and metastatic disease treatments.

  • Advanced therapeutic approaches for TNBC
  • Adjuvant therapy optimization
  • Personalized treatment strategies

Trials evaluate novel drug combinations and targeted therapies to improve patient outcomes.

03 Gastrointestinal Oncology

Research focusing on various digestive system cancers, including gastric cancer, colorectal cancer, and pancreatic cancer. Studies evaluate both early-stage and advanced disease treatments.

  • Advanced gastric cancer therapies
  • Preoperative treatment strategies
  • Novel combination approaches

Investigations aim to improve surgical outcomes and treatment effectiveness for GI cancers.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.